Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025
Year: 2025
Type: article
Study design: Observational Study
Abstract: We measured effectiveness of nirsevimab against laboratory-confirmed respiratory syncytial virus (RSV) infection in a test-negative case-control study among children aged < 24 months hospitalised for severe acute respiratory infection in three European countries. The overall effectiveness in the 2024/25 season among 2,201 children was 79% (95% CI: 58 to 89) and 85%, 78% and 69% at < 30, 30-89 and 90-215 days since immunisation. Immunisation was effective for preventing RSV-related hospitalisation in children, but effectiveness by time since immunisation needs monitoring in future seasons.
Source: Eurosurveillance
Authors: Camelia Savulescu, Iris Ganser, Nathalie Nicolay, Adrien Lajot, Sandra Campos, Iván Martínez-Baz, Ana Paula Rodrigues, Mathil Vandromme, Marta Cara-Rodríguez, Aitziber Echeverría, Vânia Gaio, Marie-Pierre Parsy, Ana Roldan Garrido, Jesús Castilla, Raquel Guiomar, Sabrina Bacci, Angela MC Rose
Institutions: European Centre for Disease Prevention and Control, Sciensano (Belgium), Universidad Nacional de Educación a Distancia, Instituto de Salud Carlos III, Instituto de Salud Pública de Navarra, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, National Institute of Health Dr. Ricardo Jorge, Complejo Hospitalario de Cáceres, Centre Hospitalier de Wallonie Picarde, Junta de Andalucía
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Award: G4503485868
OpenAlex ID: W4416230379